Ultimovacs ASA

Oslo Stock Exchange ULTI.OL

Ultimovacs ASA Market Capitalization on January 14, 2025: USD 6.40 M

Ultimovacs ASA Market Capitalization is USD 6.40 M on January 14, 2025, a -98.57% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Ultimovacs ASA 52-week high Market Capitalization is USD 525.91 M on February 20, 2024, which is 8,111.17% above the current Market Capitalization.
Ultimovacs ASA 52-week low Market Capitalization is USD 5.13 M on October 09, 2024, which is -19.90% below the current Market Capitalization.
Ultimovacs ASA average Market Capitalization for the last 52 weeks is USD 81.92 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Oslo Stock Exchange: ULTI.OL

Ultimovacs ASA

CEO	Dr. Carlos de Sousa
IPO Date	June 3, 2019
Location	Norway
Headquarters	Ullernchausséen 64
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.

Key trends

Past 5 years